Literature DB >> 12571464

Self-reported initial management of childhood idiopathic thrombocytopenic purpura: results of a survey of members of the American Society of Pediatric Hematology/Oncology, 2001.

Sara K Vesely1, George R Buchanan, Leah Adix, James N George, Alan R Cohen, Victor S Blanchette, Thomas Kühne.   

Abstract

The purpose of this study was to update physicians' self-reported initial management practices for childhood idiopathic thrombocytopenic purpura (ITP) from an initial survey in 1997. A questionnaire was sent by e-mail in October 2001 to 753 members of the American Society of Pediatric Hematology/Oncology (ASPH/O). The questionnaire had 14 questions, based on the clinical presentation of a 5-year-old boy with ITP, a platelet count of 7,000/microL, scattered petechiae, and no mucous membrane bleeding. Two hundred eighteen (29%) surveys were returned. In response to questions regarding initial treatment, 33% of physicians said they would always administer drug therapy, 38% usually, 15% sometimes, and 14% rarely/never. When asked which agent would be used if drug treatment were prescribed, 45% reported anti-D, 33% IVIG, 20% prednisone, and 2% other regimens. Only 34% of physicians would always or usually hospitalize such a patient. Hospitalization was more likely if a physician responded that he or she would always or usually use drug therapy. Physicians who saw more ITP patients were more likely to self-report sometimes or rarely/never prescribing drug therapy. Self-reported initial management of ITP by ASPH/O members in 2001 is similar to 1997 regarding the percentage of pediatric hematologists who would not use drug therapy. Among physicians who would use drug treatment, there was an increased use of anti-D and decreased use of IVIG and prednisone. This information provides the basis for designing a randomized clinical trial to compare the effect of different management strategies on the outcomes of bleeding symptoms, side effects of therapy, costs, and quality of life.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12571464     DOI: 10.1097/00043426-200302000-00009

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  6 in total

1.  Physician decision making in selection of second-line treatments in immune thrombocytopenia in children.

Authors:  Rachael F Grace; Jenny M Despotovic; Carolyn M Bennett; James B Bussel; Michelle Neier; Cindy Neunert; Shelley E Crary; Yves D Pastore; Robert J Klaassen; Jennifer A Rothman; Kerry Hege; Vicky R Breakey; Melissa J Rose; Kristin A Shimano; George R Buchanan; Amy Geddis; Kristina M Haley; Adonis Lorenzana; Alexis Thompson; Michael Jeng; Ellis J Neufeld; Travis Brown; Peter W Forbes; Michele P Lambert
Journal:  Am J Hematol       Date:  2018-05-06       Impact factor: 10.047

Review 2.  Treatment of immune thrombocytopenic purpura in children : current concepts.

Authors:  Aziza T Shad; Corina E Gonzalez; S G Sandler
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

3.  Severe hemorrhage in children with newly diagnosed immune thrombocytopenic purpura.

Authors:  Cindy E Neunert; George R Buchanan; Paul Imbach; Paula H B Bolton-Maggs; Carolyn M Bennett; Ellis J Neufeld; Sara K Vesely; Leah Adix; Victor S Blanchette; Thomas Kühne
Journal:  Blood       Date:  2008-08-12       Impact factor: 22.113

4.  Management of primary immune thrombocytopenia, 2012: a survey of oklahoma hematologists-oncologists.

Authors:  Kaelyn H Lu; James N George; Sara K Vesely; Deirdra R Terrell
Journal:  Am J Med Sci       Date:  2014-03       Impact factor: 2.378

5.  Intravenous immune globulin versus intravenous anti-D immune globulin for the treatment of acute immune thrombocytopenic purpura.

Authors:  Elham Shahgholi; Parvaneh Vosough; Kambiz Sotoudeh; Khadijeh Arjomandi; Shahla Ansari; Soraya Salehi; Mohammad Faranoush; Mohammad Ali Ehsani
Journal:  Indian J Pediatr       Date:  2009-02-04       Impact factor: 1.967

6.  Hospitalizations in pediatric patients with immune thrombocytopenia in the United States.

Authors:  Michael D Tarantino; Mark Danese; Robert J Klaassen; Jennifer Duryea; Melissa Eisen; James Bussel
Journal:  Platelets       Date:  2016-03-04       Impact factor: 3.862

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.